Light physical activity was associated with improved femoral neck and total hip BMD among young adults with obesity and overweight.

Ketamine product KETARx, produced by PharmaTher, has been approved by the FDA for use in surgical pain management.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to dusquetide (SGX945) for the treatment of Behçet disease, a type of vasculitis characterized by mucocutaneous symptoms (eg, ...

Partial sleep deprivation for multiple nights is associated with significantly increased levels of IL-6 and CRP inflammatory markers.

Lateral transiliac sacroiliac joint fusion by interventional pain management physicians using a threaded implant significantly improved pain and disability scores from baseline at 1-month follow-up.

The FDA has approved Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia in adults.

Rapid RTX infusion protocols appear to be a safe option for patients with autoimmune rheumatic diseases, potentially reducing the time spent in infusion clinics.

High continuous metabolic syndrome severity score trajectory pattern was linked to increased risk for CKD in adjusted analyses.

Complete or partial renal response and lupus low disease activity state were associated with lupus nephritis relapse risk reduction.

Long-term denosumab therapy led to improved BMD among patients with RDs, regardless of GC usage or renal function.

The Food and Drug Administration has granted Fast Track designation to CELZ-201-DDT for the treatment of degenerative disc disease.

GLP-1 RA injectable use prevalence among adults with diabetes was 26.5% in 2024, but rates were higher in some age and racial groups.